VWA5A Polyclonal Antibody
| 规格： | / 20μL / 60μL / 120μL / 200μL |
| 价格： | / ￥420 / ￥1010 / ￥1640 / ￥2365 |
货号：E-AB-14788
宿主: Rabbit
反应性: H
应用: WB,IHC
Overview
| Synonyms | BCSC1,BCSC-1,LOH11CR2A,VWA5A抗体 |
| Swissprot | O00534 |
| Source | Rabbit |
| Reactivity | Human |
| Immunogen | Recombinant protein of human VWA5A |
| Application | WB(Detection kit: E-IR-R304),IHC(Detection kit: E-IR-R213) |
| Recommended dilution | WB,,1:500-1:2000;IHC,,1:100-1:300; |
| Concentration | 0.5 mg/mL |
| Clonality | Polyclonal |
Properties
| Cellular localization | Nucleus |
| Tissue specificity | Expressed at low level in many tissues. Not expressed in 80% of tumor cell lines tested. |
| Isotype | IgG |
| Purification | Affinity purification |
| Conjugation | Unconjugated |
| Storage instructions | Store at -20℃. Avoid freeze / thaw cycles. |
| Storage buffer | PBS with 0.05% sodium azide, 50% glycerol, PH7.3 |
| Background | VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. |
Images
Western Blot analysis of adrenal pheochromocytoma tissue,Jurkat and A549 cell using VWA5A Polyclonal Antibody at dilution of 1:275
Immunohistochemistry of paraffin-embedded Human lung cancer using VWA5A Polyclonal Antibody at dilution of 1:60
Immunohistochemistry of paraffin-embedded Human liver cancer using VWA5A Polyclonal Antibody at dilution of 1:60
